Swiss drug major Novartis' chief executive Daniel Vasella stressed the need for Big Pharma companies to change in the face of a tougher market in an interview with the Wall Street Journal.
Novartis' stock, following the pharmaceuticals market trend, has dropped 25% in the last year, but showed a major turnaround in the last few months. Dr Vasella says that part of the problem was that the firm had become too big and too bureaucratic, and he was sometimes too remote from the day-to-day running of the company.
To remedy this, the company chief has employed several high level executives from outside the drug sector and started a major restructuring of the company. This includes a 25% cut in jobs at the firm's pharmaceutical headquarters in Basel, Switzerland. Also, Novartis has begun soliciting advice about drug candidates from health systems and other authorities in order to guide development.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze